Download 2. Fulvestrant for the treatment of locally advanced or metastatic

1.
Robertson JFR, Osborne CK et al. Fulvestrant versus anastrozole for the treatment of advanced
breast carcinoma in postmenopausal women: a prospective combined analysis of two multicentre
trials. Cancer 2003;98:229-38.
2.
Fulvestrant for the treatment of locally advanced or metastatic breast cancer. National
Institute for Health and Clinical Excellence Technical Guidance, Dec 2011.
http://guidance.nice.org.uk/TA239
3.
Di Leo A, Jerusalem G et al. Final analysis of overall survival for the phase III CONFIRM trial:
fulvestrant 500mg versus 250mg. Cancer Research. 2012;72(Suppl 3)
doi:10.1158/0008-5472.SABCS12-S1-4. [Abstract] 35th Annual CTRC-AACR San Antonio Breast
Cancer Symposium, Dec 4-8, 2012; San Antonio, TX.
4.
NCCN (National Comprehensive Cancer Network) Practice Guidelines – Breast cancer, v.3.2012 .
http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
5.
Cardoso F, Harbeck N et al on behalf of the ESMO Guidelines Working Group. Locally recurrent
or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and
follow-up. Annals Oncol 2012;23(Suppl 7):vii11-vii19.
6.
Chia S, Gradishar W. Double-blind, randomized placebo controlled trial of fulvestrant compared
with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women
with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol
2008;26:1664-1670.
7.
Johnston S, Kilburn LS et al. Fulvestrant alone or with concomitant anastrozole vs exemestane
following progression on non-steroidal aromatase inhibitor: First results of the SoFEA trial
(CRUKE/03/021 & CRUK/09/007) (ISRCTN44195747). EJC 2011;47(Suppl 2). [Abstract]
8. Faslodex HK Prescribing Information. Jan 2010 ONC.000-195-878.5.0
9. Di Leo A et al. Results of the CONFIRM phase III trial comparing fulvestrant 500mg in
postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin
Oncol 2010;28:4594-4600
10. Howell A et al. Fulvestrant, formerly ICI 182, 780, is an effective as anastrozole in
postmenopausal women with advanced breast cancer progressing after prior endocrine
treatment. J Clin Oncol 2002;20:3396-3403.
11. Obsborne CK et al. Double-blind, randomized trial comparing the efficacy and
tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced
breast cancer progressing on prior endocrine therapy: results of a North America trial. J
Clin Oncol 2002;20:3386-3395.
12. Chia S et al. Double-blind, randomized placebo controlled trial of fulvestrant compared
with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal
women with hormone receptor-positive, advanced breast cancer: results from EFECT. J
Clin Oncol 2008:26:1664-1670.
13. Chia S et al. Fulvestrant vs exemestane following non-steroidal aromatase inhibitor
failure: first overall survival data from the EFECT trial [abstract no. 2091]. 30th Annual
San Antonio Breast Cancer Symposium; 2007 Dec 13-16; San Antonio (TX)
14. Kuter, I. Dose-dependent change in biomarkers during neoadjuvant endocrine therapy
with fulvestrant: results from NEWEST, a randomized phase II study. Breast Cancer Res
Treat 2012;133:237-246.
15. Pajk B et al. Anti-tumor activity of capecitabine and vinorelbine in patients with
anthracycline- and taxane-pretreated metastatic breast cancer: findings from the EORTC
10001 randomized phase II trial. The Breast 2008;17:180-185.
16. Udom DI et al. Two weekly vinorelbine: administration in patients who have received at
least two prior chemotherapy regimes for advanced breast cancer. Euro J of Cancer
2000;36:177-182
17. El Helw L, Coleman RE. Reduced dose capecitabine is an effective and well-tolerated
treatment in patients with metastatic breast cancer. The Breast 2005;14:368-374
18. Fumoleau P et al. Multicentre, phase II study evaluating capecitabine monotherapy in
patients with anthracycline- and taxane-pretreated metastatic breast cancer. Euro J Cancer
2004;40:536-542
19. Lee SH et al. Capecitabine monotherapy in patients with anthracycline- and
taxane-pretreated metastatic breast cancer. Med Oncol 2004;21(3):223-231.
20. Reichardt P et al. Multicentre phase II study of oral capecitabine (Xeloda) in patients with
metastatic breast cancer relapsing after treatment with a taxane-containing therapy Ann
Oncol 2003;14:1227-1233.
21. Wist EA et al. Oral capecitabine in anthracycline- and taxane-pretreated
advanced/metastatic breast cancer. Acta Oncologica 2004;43(2):186-189.
22. Venturini M et al. An open-label, multicentre study of outpatient capecitabine
monotherapy in 631 patients with pretreated advanced breast cancer. Oncology
2007;72:51-57.
23. Yap YS et al. Clinical efficacy of capecitabine as first-line chemotherapy in metastatic
breast cancer – how low can you go? The Breast 2007;16:420-424